{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:03:48Z","timestamp":1794618228046,"version":"4.9.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Opinion statement<\/jats:title><jats:p>The incidence of metastatic pheochromocytoma (PHEO) and paraganglioma (PGL) may occur in as many as 35% of patients particularly with PGL and even more frequently in those with specific mutations. Biochemical, morphological, and molecular markers have been investigated for use in the distinction of benign from malignant PHEO\/PGL. PHEO\/PGL metastasizes via hematogenous or lymphatic routes and shows differences based on mutational status. The most common sites of involvement in patients that have an SDHB mutation are the bone (78%), lungs (45%), lymph nodes (36%), and liver (35%). In patients with sporadic PHEO\/PGL, the most common sites of metastasis are the bones (64%), lungs (47%), lymph nodes (36%), and liver (32%). Metastases may be present at presentation or may occur later. Metastases to the liver and lungs are associated with a shorter survival. Overall, the estimated 5-year survival rates are between 34 and 74%. Currently, treatments for metastatic PHEO\/PGL are essentially palliative. Surgery is potentially curative; however, tumor dissemination limits the chance for a curative resection. When surgical intervention is not amenable, the therapeutic options include radiolabeled MIBG (Azedra\u00ae\u2014iobenguane 131 was recently FDA-approved for patients &gt;\u200912\u00a0years and older with iobenguane scan positive) or systemic chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD) with an overall objective response rate (ORR) of less than 40%; however, it is not clear if the administration of CVD impacts overall survival, as nearly all patients develop progressive and ultimately fatal disease. Other treatment modalities under investigation include cytoreductive techniques, novel radiopharmaceuticals, chemotherapy, radiotherapy, immunotherapy, and experimental therapies. Here we are discussing emerging treatment for advanced\/metastatic PHEO\/PGL.<\/jats:p>","DOI":"10.1007\/s11864-020-00787-z","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T17:05:57Z","timestamp":1598720757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Emerging Treatments for Advanced\/Metastatic Pheochromocytoma and Paraganglioma"],"prefix":"10.1007","volume":"21","author":[{"given":"Maran","family":"Ilanchezhian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-4030","authenticated-orcid":false,"given":"Jaydira","family":"Del Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,29]]},"reference":[{"issue":"9486","key":"787_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s0140-6736(05)67139-5","volume":"366","author":"JW Lenders","year":"2005","unstructured":"Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet (London, England). 2005;366(9486):665\u201375. https:\/\/doi.org\/10.1016\/s0140-6736(05)67139-5.","journal-title":"Lancet (London, England)"},{"key":"787_CR2","unstructured":"DeLellis RA. Pathology and genetics of tumours of endocrine organs. IARC; 2004."},{"issue":"11","key":"787_CR3","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1210\/jcem.86.11.8034","volume":"86","author":"D Erickson","year":"2001","unstructured":"Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86(11):5210\u20136. https:\/\/doi.org\/10.1210\/jcem.86.11.8034.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"787_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jamcollsurg.2009.09.022","volume":"209","author":"MA Guerrero","year":"2009","unstructured":"Guerrero MA, Schreinemakers JM, Vriens MR, Suh I, Hwang J, Shen WT, et al. Clinical spectrum of pheochromocytoma. J Am Coll Surg. 2009;209(6):727\u201332. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2009.09.022.","journal-title":"J Am Coll Surg"},{"issue":"3","key":"787_CR5","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/ki.1991.244","volume":"40","author":"EL Bravo","year":"1991","unstructured":"Bravo EL. Pheochromocytoma: new concepts and future trends. Kidney Int. 1991;40(3):544\u201356. https:\/\/doi.org\/10.1038\/ki.1991.244.","journal-title":"Kidney Int"},{"issue":"11","key":"787_CR6","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","volume":"287","author":"JW Lenders","year":"2002","unstructured":"Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best. Jama. 2002;287(11):1427\u201334. https:\/\/doi.org\/10.1001\/jama.287.11.1427.","journal-title":"Jama."},{"issue":"3","key":"787_CR7","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1530\/eje-14-0113","volume":"171","author":"E Baudin","year":"2014","unstructured":"Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, et al. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014;171(3):R111\u201322. https:\/\/doi.org\/10.1530\/eje-14-0113.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"787_CR8","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1210\/jc.2013-1907","volume":"98","author":"S Hescot","year":"2013","unstructured":"Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2013;98(10):4006\u201312. https:\/\/doi.org\/10.1210\/jc.2013-1907.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"787_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","volume":"15","author":"C Jimenez","year":"2013","unstructured":"Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M, et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep. 2013;15(4):356\u201371. https:\/\/doi.org\/10.1007\/s11912-013-0320-x.","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"787_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11912-017-0643-0","volume":"19","author":"P Jimenez","year":"2017","unstructured":"Jimenez P, Tatsui C, Jessop A, Thosani S, Jimenez C. Treatment for malignant pheochromocytomas and paragangliomas: 5 years of progress. Curr Oncol Rep. 2017;19(12):83. https:\/\/doi.org\/10.1007\/s11912-017-0643-0.","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"787_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1055\/s-0031-1,299,707","volume":"44","author":"PF Plouin","year":"2012","unstructured":"Plouin PF, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier ND, Baudin E, et al. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Hormone Metab Res = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2012;44(5):390\u20139. https:\/\/doi.org\/10.1055\/s-0031-1,299,707.","journal-title":"Hormone Metab Res = Hormon- und Stoffwechselforschung = Hormones et metabolisme"},{"issue":"9","key":"787_CR12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1055\/s-0029-1,231,025","volume":"41","author":"R Adjall\u00e9","year":"2009","unstructured":"Adjall\u00e9 R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Hormone and metabolic research\u2009= Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2009;41(9):687\u201396. https:\/\/doi.org\/10.1055\/s-0029-1,231,025.","journal-title":"Hormone and metabolic research\u2009= Hormon- und Stoffwechselforschung = Hormones et metabolisme"},{"key":"787_CR13","doi-asserted-by":"publisher","first-page":"138573","DOI":"10.1155\/2015\/138573","volume":"2015","author":"A Luchetti","year":"2015","unstructured":"Luchetti A, Walsh D, Rodger F, Clark G, Martin T, Irving R, et al. Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis. Int J Endocrinol. 2015;2015:138573. https:\/\/doi.org\/10.1155\/2015\/138573.","journal-title":"Int J Endocrinol"},{"issue":"6","key":"787_CR14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.4158\/ep161718.Ra","volume":"23","author":"G Gupta","year":"2017","unstructured":"Gupta G, Pacak K. Precision medicine: an update on genotype\/biochemical phenotype relationships in pheochromocytoma\/paraganglioma patients. Endocr Pract: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2017;23(6):690\u2013704. https:\/\/doi.org\/10.4158\/ep161718.Ra.","journal-title":"Endocr Pract: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists"},{"key":"787_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2016.01.022","volume":"100","author":"S Pillai","year":"2016","unstructured":"Pillai S, Gopalan V, Smith RA, Lam AK. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. Crit Rev Oncol Hematol. 2016;100:190\u2013208. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.01.022.","journal-title":"Crit Rev Oncol Hematol"},{"key":"787_CR16","doi-asserted-by":"publisher","unstructured":"\u2022 Crona J, Ta\u00efeb D, Pacak K. New Perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr Rev. 2017;38(6):489\u2013515. https:\/\/doi.org\/10.1210\/er.2017-00062 Retrospective study detailing the differences between sporadic and SDHB germline PHEOs\/PGLs.","DOI":"10.1210\/er.2017-00062"},{"key":"787_CR17","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 N\u00f6lting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, Grossman A, et al. Current management of pheochromocytoma\/paraganglioma: a guide for the practicing clinician in the era of precision medicine. Cancers. 2019;11(10):1505. https:\/\/doi.org\/10.3390\/cancers11101505 Retrospective study detailing the differences between sporadic and SDHB germline PHEOs\/PGLs.","DOI":"10.3390\/cancers11101505"},{"key":"787_CR18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3389\/fendo.2018.00515","volume":"9","author":"R Alrezk","year":"2018","unstructured":"Alrezk R, Suarez A, Tena I, Pacak K. Update of pheochromocytoma syndromes: genetics, biochemical evaluation, and imaging. Front Endocrinol. 2018;9:515. https:\/\/doi.org\/10.3389\/fendo.2018.00515.","journal-title":"Front Endocrinol"},{"key":"787_CR19","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Jochmanova I, Pacak K. Genomic landscape of pheochromocytoma and paraganglioma. Trends in cancer. 2018;4(1):6\u20139. https:\/\/doi.org\/10.1016\/j.trecan.2017.11.001 Retrospective study detailing the differences between sporadic and SDHB germline PHEOs\/PGLs.","DOI":"10.1016\/j.trecan.2017.11.001"},{"issue":"20","key":"787_CR20","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1093\/hmg\/ddr324","volume":"20","author":"N Burnichon","year":"2011","unstructured":"Burnichon N, Vescovo L, Amar L, Lib\u00e9 R, de Reynies A, Venisse A, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011;20(20):3974\u201385. https:\/\/doi.org\/10.1093\/hmg\/ddr324.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"787_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31(2):181\u201393. https:\/\/doi.org\/10.1016\/j.ccell.2017.01.001.","journal-title":"Cancer Cell"},{"issue":"1","key":"787_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1086\/321282","volume":"69","author":"D Astuti","year":"2001","unstructured":"Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;69(1):49\u201354. https:\/\/doi.org\/10.1086\/321282.","journal-title":"Am J Hum Genet"},{"issue":"10","key":"787_CR23","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1210\/jc.2007-0709","volume":"92","author":"L Amar","year":"2007","unstructured":"Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007;92(10):3822\u20138. https:\/\/doi.org\/10.1210\/jc.2007-0709.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"787_CR24","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1210\/jc.2005-1862","volume":"91","author":"DE Benn","year":"2006","unstructured":"Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, et al. Clinical presentation and penetrance of pheochromocytoma\/paraganglioma syndromes. J Clin Endocrinol Metab. 2006;91(3):827\u201336. https:\/\/doi.org\/10.1210\/jc.2005-1862.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"787_CR25","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1210\/jc.2006-0423","volume":"91","author":"FM Brouwers","year":"2006","unstructured":"Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91(11):4505\u20139. https:\/\/doi.org\/10.1210\/jc.2006-0423.","journal-title":"J Clin Endocrinol Metab"},{"key":"787_CR26","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Turkova H, Prodanov T, Maly M, Martucci V, Adams K, Widimsky J Jr, et al. Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma\/paraganglioma: an national institutes of health study. Endocr Pract: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2016;22(3):302\u201314. https:\/\/doi.org\/10.4158\/ep15725.Or Retrospective study detailing the differences between sporadic and SDHB germline PHEOs\/PGLs.","DOI":"10.4158\/ep15725.Or"},{"issue":"34","key":"787_CR27","doi-asserted-by":"publisher","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","volume":"23","author":"L Amar","year":"2005","unstructured":"Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(34):8812\u20138. https:\/\/doi.org\/10.1200\/JCO.2005.03.1484.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"787_CR28","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/jnci\/djs188","volume":"104","author":"HJ Timmers","year":"2012","unstructured":"Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104(9):700\u20138. https:\/\/doi.org\/10.1093\/jnci\/djs188.","journal-title":"J Natl Cancer Inst"},{"key":"787_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fonc.2019.00053","volume":"9","author":"A Jha","year":"2019","unstructured":"Jha A, de Luna K, Balili CA, Millo C, Paraiso CA, Ling A, et al. Clinical, diagnostic, and treatment characteristics of SDHA-related metastatic pheochromocytoma and paraganglioma. Front Oncol. 2019;9:53. https:\/\/doi.org\/10.3389\/fonc.2019.00053.","journal-title":"Front Oncol"},{"issue":"2","key":"787_CR30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1210\/jc.2002-021251","volume":"88","author":"AM Sawka","year":"2003","unstructured":"Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-h urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003;88(2):553\u20138. https:\/\/doi.org\/10.1210\/jc.2002-021251.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"787_CR31","doi-asserted-by":"publisher","first-page":"R627","DOI":"10.1530\/erc-19-0165","volume":"26","author":"D Ta\u00efeb","year":"2019","unstructured":"Ta\u00efeb D, Jha A, Treglia G, Pacak K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer. 2019;26(11):R627\u2013r52. https:\/\/doi.org\/10.1530\/erc-19-0165.","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"787_CR32","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","volume":"46","author":"D Ta\u00efeb","year":"2019","unstructured":"Ta\u00efeb D, Hicks RJ, Hindi\u00e9 E, Guillet BA, Avram A, Ghedini P, et al. European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46(10):2112\u201337. https:\/\/doi.org\/10.1007\/s00259-019-04398-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"787_CR33","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1210\/jc.2002-020312","volume":"87","author":"AL Young","year":"2002","unstructured":"Young AL, Baysal BE, Deb A, Young WF Jr. Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. J Clin Endocrinol Metab. 2002;87(9):4101\u20135. https:\/\/doi.org\/10.1210\/jc.2002-020312.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"787_CR34","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","volume":"48","author":"G Eisenhofer","year":"2012","unstructured":"Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48(11):1739\u201349. https:\/\/doi.org\/10.1016\/j.ejca.2011.07.016.","journal-title":"Eur J Cancer"},{"issue":"7","key":"787_CR35","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1007\/s002689900139","volume":"20","author":"DS O\u2019Riordain","year":"1996","unstructured":"O\u2019Riordain DS, Young WF Jr, Grant CS, Carney JA, van Heerden JA. Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg. 1996;20(7):916\u201321 discussion 22.","journal-title":"World J Surg"},{"issue":"10","key":"787_CR36","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/j.1365-2362.2011.02518.x","volume":"41","author":"T Zelinka","year":"2011","unstructured":"Zelinka T, Musil Z, Duskova J, Burton D, Merino MJ, Milosevic D, et al. Metastatic pheochromocytoma: does the size and age matter. Eur J Clin Investig. 2011;41(10):1121\u20138. https:\/\/doi.org\/10.1111\/j.1365-2362.2011.02518.x.","journal-title":"Eur J Clin Investig"},{"issue":"3","key":"787_CR37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1373\/clinchem.2010.153320","volume":"57","author":"G Eisenhofer","year":"2011","unstructured":"Eisenhofer G, Lenders JW, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2011;57(3):411\u201320. https:\/\/doi.org\/10.1373\/clinchem.2010.153320.","journal-title":"Clin Chem"},{"issue":"3","key":"787_CR38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1210\/jc.2010-1946","volume":"96","author":"M Ayala-Ramirez","year":"2011","unstructured":"Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96(3):717\u201325. https:\/\/doi.org\/10.1210\/jc.2010-1946.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"787_CR39","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/BF03348026","volume":"20","author":"KC Loh","year":"1997","unstructured":"Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Investig. 1997;20(11):648\u201358.","journal-title":"J Endocrinol Investig"},{"issue":"8","key":"787_CR40","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1245\/s10434-008-9977-z","volume":"15","author":"M Makeieff","year":"2008","unstructured":"Makeieff M, Raingeard I, Alric P, Bonafe A, Guerrier B, Marty-Ane C. Surgical management of carotid body tumors. Ann Surg Oncol. 2008;15(8):2180\u20136. https:\/\/doi.org\/10.1245\/s10434-008-9977-z.","journal-title":"Ann Surg Oncol"},{"issue":"15_suppl","key":"787_CR41","doi-asserted-by":"publisher","first-page":"TPS4159-TPS","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4159","volume":"37","author":"F Lin","year":"2019","unstructured":"Lin F, Rivero JD, Carrasquillo JA, Jha A, Gonzales MK, Lindenberg L, et al. Phase 2 trial of Lu-177-DOTATATE in inoperable pheochromocytoma\/paraganglioma. J Clin Oncol. 2019;37(15_suppl):TPS4159-TPS. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS4159.","journal-title":"J Clin Oncol"},{"issue":"6","key":"787_CR42","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/cen.14106","volume":"91","author":"S Satapathy","year":"2019","unstructured":"Satapathy S, Mittal BR, Bhansali A. Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis. Clin Endocrinol. 2019;91(6):718\u201327. https:\/\/doi.org\/10.1111\/cen.14106.","journal-title":"Clin Endocrinol"},{"key":"787_CR43","unstructured":"Pacak K, Del Rivero J. Pheochromocytoma. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright \u00a9 2000-2020, MDText.com, Inc.; 2000. Accessed 23 March 2020."},{"issue":"1","key":"787_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12022-011-9189-0","volume":"23","author":"J Favier","year":"2012","unstructured":"Favier J, Igaz P, Burnichon N, Amar L, Lib\u00e9 R, Badoual C, et al. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Endocr Pathol. 2012;23(1):34\u201342. https:\/\/doi.org\/10.1007\/s12022-011-9189-0.","journal-title":"Endocr Pathol"},{"issue":"4","key":"787_CR45","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/cancers11040436","volume":"11","author":"Y Pang","year":"2019","unstructured":"Pang Y, Liu Y, Pacak K, Yang C. Pheochromocytomas and paragangliomas: from genetic diversity to targeted therapies. Cancers. 2019;11(4):436. https:\/\/doi.org\/10.3390\/cancers11040436.","journal-title":"Cancers"},{"issue":"4","key":"787_CR46","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.3390\/ijms15045323","volume":"15","author":"CV Ferreira","year":"2014","unstructured":"Ferreira CV, Siqueira DR, Romitti M, Ceolin L, Brasil BA, Meurer L, et al. Role of VEGF-A and its receptors in sporadic and MEN2-associated pheochromocytoma. Int J Mol Sci. 2014;15(4):5323\u201336. https:\/\/doi.org\/10.3390\/ijms15045323.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"787_CR47","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1210\/jc.2012-2356","volume":"97","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012;97(11):4040\u201350. https:\/\/doi.org\/10.1210\/jc.2012-2356.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"787_CR48","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/jco.2008.19.9380","volume":"27","author":"NM Hahn","year":"2009","unstructured":"Hahn NM, Reckova M, Cheng L, Baldridge LA, Cummings OW, Sweeney CJ. Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(3):460\u20133. https:\/\/doi.org\/10.1200\/jco.2008.19.9380.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"787_CR49","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1210\/jc.2008-1972","volume":"94","author":"C Jimenez","year":"2009","unstructured":"Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009;94(2):386\u201391. https:\/\/doi.org\/10.1210\/jc.2008-1972.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"787_CR50","first-page":"260","volume":"33","author":"K Nemoto","year":"2012","unstructured":"Nemoto K, Miura T, Shioji G, Tsuboi N. Sunitinib treatment for refractory malignant pheochromocytoma. Neuro Endocrinol Lett. 2012;33(3):260\u20134.","journal-title":"Neuro Endocrinol Lett"},{"issue":"12","key":"787_CR51","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","volume":"120","author":"GM O\u2019Kane","year":"2019","unstructured":"O\u2019Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Olney HJ, et al. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer. 2019;120(12):1113\u20139.","journal-title":"Br J Cancer"},{"issue":"7_suppl","key":"787_CR52","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1200\/jco.2015.33.7_suppl.457","volume":"33","author":"MEB Pichun","year":"2015","unstructured":"Pichun MEB, Edgerly M, Velarde M, Bates SE, Daerr R, Adams K, et al. Phase II clinical trial of axitinib in metastatic pheochromocytomas and paraganlgiomas (P\/PG): preliminary results. J Clin Oncol. 2015;33(7_suppl):457. https:\/\/doi.org\/10.1200\/jco.2015.33.7_suppl.457.","journal-title":"J Clin Oncol"},{"issue":"10","key":"787_CR53","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1056\/NEJMoa1205119","volume":"367","author":"Z Zhuang","year":"2012","unstructured":"Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med. 2012;367(10):922\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1205119.","journal-title":"N Engl J Med"},{"issue":"2","key":"787_CR54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.5507\/bp.2014.021","volume":"158","author":"I Jochmanova","year":"2014","unstructured":"Jochmanova I, Lazurova I. A new twist in neuroendocrine tumor research: Pacak-Zhuang syndrome, HIF-2alpha as the major player in its pathogenesis and future therapeutic options. Biomed Papers Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(2):175\u201380. https:\/\/doi.org\/10.5507\/bp.2014.021.","journal-title":"Biomed Papers Med Fac Univ Palacky Olomouc Czech Repub."},{"issue":"Suppl 2","key":"787_CR55","doi-asserted-by":"publisher","first-page":"S251","DOI":"10.33549\/physiolres.932789","volume":"63","author":"I Jochmanova","year":"2014","unstructured":"Jochmanova I, Zelinka T, Widimsky J Jr, Pacak K. HIF signaling pathway in pheochromocytoma and other neuroendocrine tumors. Physiol Res. 2014;63(Suppl 2):S251\u201362.","journal-title":"Physiol Res"},{"key":"787_CR56","doi-asserted-by":"publisher","first-page":"F1000 Faculty R","DOI":"10.12688\/f1000research.13995.1","volume":"7","author":"R Toledo","year":"2018","unstructured":"Toledo R, Jimenez C. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors. F1000Res. 2018;7:F1000 Faculty Rev-148. https:\/\/doi.org\/10.12688\/f1000research.13995.1.","journal-title":"F1000Res"},{"issue":"7627","key":"787_CR57","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature19796","volume":"539","author":"W Chen","year":"2016","unstructured":"Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539(7627):112\u20137. https:\/\/doi.org\/10.1038\/nature19796.","journal-title":"Nature."},{"issue":"9","key":"787_CR58","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/jco.2017.74.2627","volume":"36","author":"KD Courtney","year":"2018","unstructured":"Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(9):867\u201374. https:\/\/doi.org\/10.1200\/jco.2017.74.2627.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"787_CR59","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1053\/j.ackd.2013.10.001","volume":"21","author":"NB Haas","year":"2014","unstructured":"Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 2014;21(1):81\u201390. https:\/\/doi.org\/10.1053\/j.ackd.2013.10.001.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"14","key":"787_CR60","doi-asserted-by":"publisher","first-page":"22313","DOI":"10.18632\/oncotarget.16224","volume":"8","author":"Y Pang","year":"2017","unstructured":"Pang Y, Yang C, Schovanek J, Wang H, Bullova P, Caisova V, et al. Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway. Oncotarget. 2017;8(14):22313\u201324. https:\/\/doi.org\/10.18632\/oncotarget.16224.","journal-title":"Oncotarget"},{"issue":"4","key":"787_CR61","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/onc.2016.225","volume":"36","author":"S Chouaib","year":"2017","unstructured":"Chouaib S, Noman MZ, Kosmatopoulos K, Curran MA. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene. 2017;36(4):439\u201345. https:\/\/doi.org\/10.1038\/onc.2016.225.","journal-title":"Oncogene."},{"key":"787_CR62","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.coph.2016.06.009","volume":"29","author":"SM Hatfield","year":"2016","unstructured":"Hatfield SM, Sitkovsky M. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1\u03b1 driven immunosuppression and improve immunotherapies of cancer. Current opinion in pharmacology. Curr Opin Pharmacol. 2016;29:90\u20136. https:\/\/doi.org\/10.1016\/j.coph.2016.06.009.","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"787_CR63","doi-asserted-by":"publisher","first-page":"e1062967","DOI":"10.1080\/2162402x.2015.1062967","volume":"5","author":"S Labiano","year":"2016","unstructured":"Labiano S, Palaz\u00f3n A, Bola\u00f1os E, Azpilikueta A, S\u00e1nchez-Paulete AR, Morales-Kastresana A, et al. Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. Oncoimmunology. 2016;5(1):e1062967. https:\/\/doi.org\/10.1080\/2162402x.2015.1062967.","journal-title":"Oncoimmunology."},{"issue":"5","key":"787_CR64","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3390\/cancers11050654","volume":"11","author":"V Caisova","year":"2019","unstructured":"Caisova V, Li L, Gupta G, Jochmanova I, Jha A, Uher O, et al. The significant reduction or complete eradication of subcutaneous and metastatic lesions in a pheochromocytoma mouse model after immunotherapy using mannan-BAM, TLR ligands, and anti-CD40. Cancers. 2019;11(5):654. https:\/\/doi.org\/10.3390\/cancers11050654.","journal-title":"Cancers"},{"issue":"5","key":"787_CR65","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1055\/s-0032-1,304,594","volume":"44","author":"A Buffet","year":"2012","unstructured":"Buffet A, Venisse A, Nau V, Roncellin I, Boccio V, Le Pottier N, et al. A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. Hormone Metab Res = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2012;44(5):359\u201366. https:\/\/doi.org\/10.1055\/s-0032-1,304,594.","journal-title":"Hormone Metab Res = Hormon- und Stoffwechselforschung = Hormones et metabolisme"},{"issue":"6","key":"787_CR66","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/ajmg.a.33384","volume":"152a","author":"RN Schimke","year":"2010","unstructured":"Schimke RN, Collins DL, Stolle CA. Paraganglioma, neuroblastoma, and a SDHB mutation: resolution of a 30-year-old mystery. Am J Med Genet A. 2010;152a(6):1531\u20135. https:\/\/doi.org\/10.1002\/ajmg.a.33384.","journal-title":"Am J Med Genet A"},{"issue":"8","key":"787_CR67","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41588-018-0170-4","volume":"50","author":"PL Sulkowski","year":"2018","unstructured":"Sulkowski PL, Sundaram RK, Oeck S, Corso CD, Liu Y, Noorbakhsh S, et al. Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nat Genet. 2018;50(8):1086\u201392. https:\/\/doi.org\/10.1038\/s41588-018-0170-4.","journal-title":"Nat Genet"},{"key":"787_CR68","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.dnarep.2018.08.022","volume":"71","author":"JM Pascal","year":"2018","unstructured":"Pascal JM. The comings and goings of PARP-1 in response to DNA damage. DNA Repair (Amst). 2018;71:177\u201382. https:\/\/doi.org\/10.1016\/j.dnarep.2018.08.022.","journal-title":"DNA Repair (Amst)"},{"issue":"14","key":"787_CR69","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1158\/1078-0432.Ccr-17-3406","volume":"24","author":"Y Pang","year":"2018","unstructured":"Pang Y, Lu Y, Caisova V, Liu Y, Bullova P, Huynh TT, et al. Targeting NAD(+)\/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster I pheochromocytoma and paraganglioma. Clin Cancer Res: an official journal of the American Association for Cancer Research. 2018;24(14):3423\u201332. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-3406.","journal-title":"Clin Cancer Res: an official journal of the American Association for Cancer Research"},{"issue":"5","key":"787_CR70","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrm2672","volume":"10","author":"XM Ma","year":"2009","unstructured":"Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nature reviews. Mol Cell Biol. 2009;10(5):307\u201318. https:\/\/doi.org\/10.1038\/nrm2672.","journal-title":"Mol Cell Biol"},{"issue":"9","key":"787_CR71","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1055\/s-0029-1,220,687","volume":"41","author":"MR Druce","year":"2009","unstructured":"Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Hormone Metab Res = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2009;41(9):697\u2013702. https:\/\/doi.org\/10.1055\/s-0029-1,220,687.","journal-title":"Hormone Metab Res = Hormon- und Stoffwechselforschung = Hormones et metabolisme"},{"issue":"24","key":"787_CR72","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.1002\/cncr.27675","volume":"118","author":"DY Oh","year":"2012","unstructured":"Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, et al. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas. Cancer. 2012;118(24):6162\u201370. https:\/\/doi.org\/10.1002\/cncr.27675.","journal-title":"Cancer."},{"issue":"7","key":"787_CR73","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrd4233","volume":"13","author":"M Kahn","year":"2014","unstructured":"Kahn M. Can we safely target the WNT pathway. Nat Rev Drug Discov. 2014;13(7):513\u201332. https:\/\/doi.org\/10.1038\/nrd4233.","journal-title":"Nat Rev Drug Discov"},{"issue":"2854","key":"787_CR74","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.3389\/fimmu.2019.02854","volume":"10","author":"E Martin-Orozco","year":"2019","unstructured":"Martin-Orozco E, Sanchez-Fernandez A, Ortiz-Parra I, Ayala-San Nicolas M. WNT signaling in tumors: the way to evade drugs and immunity. Front Immunol. 2019;10(2854):2854. https:\/\/doi.org\/10.3389\/fimmu.2019.02854.","journal-title":"Front Immunol"},{"issue":"10","key":"787_CR75","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331.","journal-title":"N Engl J Med"},{"issue":"4","key":"787_CR76","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cen.12341","volume":"80","author":"LT van Hulsteijn","year":"2014","unstructured":"van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol. 2014;80(4):487\u2013501. https:\/\/doi.org\/10.1111\/cen.12341.","journal-title":"Clin Endocrinol"},{"key":"787_CR77","unstructured":"FDA approves AZEDRA specified use in pheochromocytomas\/paragangliomas. J Nucl Med. 2018;59(10):17. https:\/\/pubmed.ncbi.nlm.nih.gov\/30275289\/."},{"issue":"supplement 1","key":"787_CR78","first-page":"564","volume":"60","author":"D Pryma","year":"2019","unstructured":"Pryma D, Chin B, Noto R, Dillon J, Solnes L, Jensen J, et al. An update on overall survival from a multi-center, open-label, pivotal phase 2b study of AZEDRA\u00ae (iobenguane I 131) in patients with iobenguane scan positive locally advanced or metastatic pheochromocytoma\/paraganglioma (PPGL). J Nucl Med. 2019;60(supplement 1):564.","journal-title":"J Nucl Med"},{"issue":"2","key":"787_CR79","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/107327481101800205","volume":"18","author":"RH Grogan","year":"2011","unstructured":"Grogan RH, Mitmaker EJ, Duh QY. Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control: journal of the Moffitt Cancer Center. 2011;18(2):104\u201312.","journal-title":"Cancer Control: journal of the Moffitt Cancer Center"},{"key":"787_CR80","doi-asserted-by":"crossref","unstructured":"\u2022 Keiser HR, Goldstein DS, Wade JL, Douglas FL, Averbuch SD. Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension. 1985;7(3 Pt 2):I18\u201324. Nonrandomized, single-arm trial determining the efficacy of CVD combination chemotherapy in advanced PHEO.","DOI":"10.1161\/01.HYP.7.3_Pt_2.I18"},{"issue":"4","key":"787_CR81","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","volume":"109","author":"SD Averbuch","year":"1988","unstructured":"Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988;109(4):267\u201373.","journal-title":"Ann Intern Med"},{"issue":"8","key":"787_CR82","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/cncr.23812","volume":"113","author":"H Huang","year":"2008","unstructured":"Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, et al. Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. 2008;113(8):2020\u20138. https:\/\/doi.org\/10.1002\/cncr.23812.","journal-title":"Cancer."},{"issue":"2","key":"787_CR83","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","volume":"4","author":"A Tanabe","year":"2013","unstructured":"Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Hormones & cancer. 2013;4(2):103\u201310. https:\/\/doi.org\/10.1007\/s12672-013-0133-2.","journal-title":"Hormones & cancer"},{"issue":"5","key":"787_CR84","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/cen.12542","volume":"81","author":"ND Niemeijer","year":"2014","unstructured":"Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol. 2014;81(5):642\u201351. https:\/\/doi.org\/10.1111\/cen.12542.","journal-title":"Clin Endocrinol"},{"issue":"2","key":"787_CR85","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12020-009-9219-6","volume":"36","author":"J He","year":"2009","unstructured":"He J, Makey D, Fojo T, Adams KT, Havekes B, Eisenhofer G, et al. Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma. Endocrine. 2009;36(2):189\u201393. https:\/\/doi.org\/10.1007\/s12020-009-9219-6.","journal-title":"Endocrine."},{"issue":"7","key":"787_CR86","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s002590100541","volume":"28","author":"JC Reubi","year":"2001","unstructured":"Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28(7):836\u201346.","journal-title":"Eur J Nucl Med"},{"issue":"11","key":"787_CR87","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1210\/jc.2003-030262","volume":"88","author":"J Mundschenk","year":"2003","unstructured":"Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, Steinke R, et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab. 2003;88(11):5150\u20137. https:\/\/doi.org\/10.1210\/jc.2003-030262.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"787_CR88","first-page":"1599","volume":"47","author":"M van Essen","year":"2006","unstructured":"van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47(10):1599\u2013606.","journal-title":"J Nucl Med"},{"issue":"10","key":"787_CR89","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.2967\/jnumed.110.075226","volume":"51","author":"Y Menda","year":"2010","unstructured":"Menda Y, O\u2019Dorisio MS, Kao S, Khanna G, Michael S, Connolly M, et al. Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med. 2010;51(10):1524\u201331. https:\/\/doi.org\/10.2967\/jnumed.110.075226.","journal-title":"J Nucl Med"},{"issue":"4","key":"787_CR90","first-page":"334","volume":"52","author":"F Forrer","year":"2008","unstructured":"Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52(4):334\u201340.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"9","key":"787_CR91","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1210\/jc.2017-00816","volume":"102","author":"G Kong","year":"2017","unstructured":"Kong G, Grozinsky-Glasberg S, Hofman MS, Callahan J, Meirovitz A, Maimon O, et al. Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma. J Clin Endocrinol Metab. 2017;102(9):3278\u201387. https:\/\/doi.org\/10.1210\/jc.2017-00816.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"787_CR92","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/jso.24553","volume":"115","author":"K Nastos","year":"2017","unstructured":"Nastos K, Cheung VTF, Toumpanakis C, Navalkissoor S, Quigley AM, Caplin M, et al. Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas. J Surg Oncol. 2017;115(4):425\u201334. https:\/\/doi.org\/10.1002\/jso.24553.","journal-title":"J Surg Oncol"},{"issue":"12","key":"787_CR93","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.3390\/ijms20123049","volume":"20","author":"AK Stueven","year":"2019","unstructured":"Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci. 2019;20(12):3049. https:\/\/doi.org\/10.3390\/ijms20123049.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"787_CR94","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s13139-019-00629-3","volume":"54","author":"A Jha","year":"2020","unstructured":"Jha A, Patel M, Baker E, Gonzales MK, Ling A, Millo C, et al. Role of (68)Ga-DOTATATE PET\/CT in a case of SDHB-related pterygopalatine fossa paraganglioma successfully controlled with octreotide. Nucl Med Mol Imaging. 2020;54(1):48\u201352. https:\/\/doi.org\/10.1007\/s13139-019-00629-3.","journal-title":"Nucl Med Mol Imaging"},{"issue":"7","key":"787_CR95","first-page":"1093","volume":"3","author":"M Dhodapkar","year":"1997","unstructured":"Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res: an official journal of the American Association for Cancer Research. 1997;3(7):1093\u2013100.","journal-title":"Clin Cancer Res: an official journal of the American Association for Cancer Research"},{"issue":"1","key":"787_CR96","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","volume":"18","author":"MR Middleton","year":"2000","unstructured":"Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(1):158\u201366.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"787_CR97","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","volume":"15","author":"MH Kulke","year":"2009","unstructured":"Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res: an official journal of the American Association for Cancer Research. 2009;15(1):338\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1476.","journal-title":"Clin Cancer Res: an official journal of the American Association for Cancer Research"},{"issue":"11","key":"787_CR98","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","volume":"135","author":"J Hadoux","year":"2014","unstructured":"Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. 2014;135(11):2711\u201320. https:\/\/doi.org\/10.1002\/ijc.28913.","journal-title":"Int J Cancer"},{"issue":"9","key":"787_CR99","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1055\/s-0029-1,224,135","volume":"41","author":"EL Bravo","year":"2009","unstructured":"Bravo EL, Kalmadi SR, Gill I. Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report. Hormone Metab Res=Hormon- und Stoffwechselforschung=Hormones et metabolisme. 2009;41(9):703\u20136. https:\/\/doi.org\/10.1055\/s-0029-1,224,135.","journal-title":"Hormone Metab Res=Hormon- und Stoffwechselforschung=Hormones et metabolisme"},{"key":"787_CR100","doi-asserted-by":"publisher","first-page":"117955491876336","DOI":"10.1177\/1179554918763367","volume":"12","author":"I Tena","year":"2018","unstructured":"Tena I, Gupta G, Tajahuerce M, Benavent M, Cifri\u00e1n M, Falcon A, et al. Successful second-line metronomic temozolomide in metastatic paraganglioma: case reports and review of the literature. Clin Med Insights Oncol. 2018;12:1179554918763367. https:\/\/doi.org\/10.1177\/1179554918763367.","journal-title":"Clin Med Insights Oncol"},{"issue":"10","key":"787_CR101","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","volume":"9","author":"AF Farago","year":"2019","unstructured":"Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov. 2019;9(10):1372\u201387. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0582.","journal-title":"Cancer Discov"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00787-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-020-00787-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00787-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T23:28:26Z","timestamp":1630193306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-020-00787-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,29]]},"references-count":101,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["787"],"URL":"https:\/\/doi.org\/10.1007\/s11864-020-00787-z","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,29]]},"assertion":[{"value":"29 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Maran Ilanchezhian declares that he has no conflict of interest. Abhishek Jha declares that he has no conflict of interest. Karel Pacak declares that he has no conflict of interest. Jaydira Del Rivero declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"85"}}